4.8 Review

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

Journal

CELL
Volume 181, Issue 2, Pages 236-249

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2020.03.053

Keywords

-

Funding

  1. National Cancer Institute Cancer Moonshot [U24 CA233243, U2C CA233195, U2C CA233238, U2C CA233254, U2C CA233262, U2C CA233280, U2C CA233284, U2C CA233285, U2C CA233291, U2C CA233303, U2C CA233311]
  2. Janssen Research & Development LLC
  3. Johnson Johnson
  4. Stand Up To Cancer (SU2C)-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Research Grant [SU2C-AACR-DT23-17]
  5. American Association for Cancer Research, the scientific partner of SU2C
  6. NIH National Cancer Institute [HHSN261100039, HHSN261201500003I]
  7. Early Postdoc Mobility fellowship from the Swiss National Science Foundation [P2ZHP3_181475]
  8. Klarman Cell Observatory at the Broad Institute
  9. Swiss National Science Foundation (SNF) [P2ZHP3_181475] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Crucial transitions in cancer-including tumor initiation, local expansion, metastasis, and therapeutic resistance-involve complex interactions between cells within the dynamic tumor ecosystem. Transformative single-cell genomics technologies and spatial multiplex in situ methods now provide an opportunity to interrogate this complexity at unprecedented resolution. The Human Tumor Atlas Network (HTAN), part of the National Cancer Institute (NCI) Cancer Moonshot Initiative, will establish a clinical, experimental, computational, and organizational framework to generate informative and accessible three-dimensional atlases of cancer transitions for a diverse set of tumor types. This effort complements both ongoing efforts to map healthy organs and previous large-scale cancer genomics approaches focused on bulk sequencing at a single point in time. Generating single-cell, multiparametric, longitudinal atlases and integrating them with clinical outcomes should help identify novel predictive biomarkers and features as well as therapeutically relevant cell types, cell states, and cellular interactions across transitions. The resulting tumor atlases should have a profound impact on our understanding of cancer biology and have the potential to improve cancer detection, prevention, and therapeutic discovery for better precision-medicine treatments of cancer patients and those at risk for cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available